Table 5. Adjusted OR of very early and early death among ovarian cancer patients: clinical risk factors (at time of diagnosis).
| Variables | Death within 3 mon vs. alive after 6 mon | Death within 6 mon vs. alive after 6 mon | |||
|---|---|---|---|---|---|
| Adjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value | ||
| Ascites* | |||||
| 0 | 1.000 | 1.000 | |||
| <500 | 1.357 (0.937–1.964) | 0.1060 | 1.376 (1.019–1.858) | 0.037 | |
| 500–1,999 | 1.877 (1.288–2.735) | 0.0010 | 1.941 (1.425–2.645) | <0.001 | |
| 2,000–3,999 | 2.721 (1.868–3.962) | <0.0001 | 2.768 (2.026–3.783) | <0.001 | |
| >4,000 | 2.361 (1.613–3.457) | <0.0001 | 2.174 (1.568–3.010) | <0.001 | |
| PS† | |||||
| 0 | 1.000 | 1.000 | |||
| 1 | 2.127 (1.522–2.972) | <0.0001 | 1.875 (1.457–2.413) | <0.001 | |
| 2 | 6.618 (4.708–9.303) | <0.0001 | 4.805 (3.669–6.292) | <0.001 | |
| 3 | 17.946 (12.005–26.826) | <0.0001 | 12.171 (8.678–17.070) | <0.001 | |
| 4 | 108.893 (50.421–235.172) | <0.0001 | 66.001 (32.332–134.732) | <0.001 | |
| ASA† | |||||
| 1 | 1.000 | 1.000 | |||
| 2 | 1.742 (1.146–2.649) | 0.0094 | 1.540 (1.135–2.088) | 0.006 | |
| 3 | 7.228 (4.734–11.037) | <0.0001 | 5.151 (3.747–7.083) | <0.001 | |
| 4 | 43.222 (23.337–80.049) | <0.0001 | 24.080 (14.084–41.171) | <0.001 | |
| 5 & 6 | 5.969 (2.777–12.833) | <0.0001 | 4.109 (2.141–7.884) | <0.001 | |
| Diagnostic procedures‡ | |||||
| None | 1.000 | 1.000 | |||
| Ultrasound-guided biopsy | 1.284 (0.852–1.934) | 0.2325 | 1.343 (0.945–1.909) | 0.100 | |
| Laparoscopy | 0.853 (0.422–1.723) | 0.6571 | 0.837 (0.469–1.493) | 0.546 | |
| Laparotomy | 1.602 (0.953–2.692) | 0.0751 | 1.514 (0.972–2.359) | 0.067 | |
| Treatment§ | |||||
| Primary surgery | 1.000 | 1.000 | |||
| None | 2.514 (1.684–3.756) | <0.0001 | 2.248 (1.569–3.200) | <0.001 | |
| NACT | 0.764 (0.570–1.025) | 0.0721 | 0.783 (0.615–0.997) | 0.048 | |
| Recidual tumorǁ: subanalysis with only patients having primary surgery | |||||
| No | 1.000 | 1.000 | |||
| Yes¶ | 12.997 (8.794–19.232) | <0.0001 | 8.325 (6.336–10.938) | <0.001 | |
| Yesǁ | 4.282 (2.684–6.830) | <0.0001 | 3.624 (2.569–5.112) | <0.001 | |
| Histology¶ | |||||
| Serous | 1.000 | 1.000 | |||
| Endometrioid | 0.268 (0.141–0.508) | <0.0001 | 0.342 (0.211–0.554) | <0.001 | |
| Clear cell | 0.213 (0.078–0.577) | 0.0024 | 0.302 (0.148–0.616) | 0.001 | |
| Mucinous | 0.716 (0.443–1.157) | 0.1726 | 1.041 (0.734–1.477) | 0.823 | |
| Sarcoma | 1.754 (1.091–2.820) | 0.0204 | 2.543 (1.780–3.634) | <0.001 | |
| Rare types | 1.920 (1.116–3.302) | 0.0184 | 1.955 (1.228–3.113) | 0.005 | |
| Reason for no treatment** | |||||
| Not relevant (treatment) | 1.000 | 1.000 | |||
| Condition | 2.859 (1.771–4.615) | <0.0001 | 2.470 (1.579–3.864) | <0.001 | |
| Wish | 11.010 (4.716–25.705) | <0.0001 | 7.801 (3.592–16.944) | <0.001 | |
| Center treatmentǁ | |||||
| No | 1.000 | 1.000 | |||
| Yes | 0.660 (0.515–0.845) | 0.0010 | 0.659 (0.535–0.806) | <0.001 | |
ASA, American Society of Anesthesiologists; CI, confidence interval; CCI, Charlson comorbidity index; NACT, neoadjuvant chemotherapy; OCCI, ovarian cancer comorbidity index; OR, odds ratio; PS, performance status.
*Adjusted for stage and histology; †Adjusted for age and stage; ‡Adjusted for age, stage, PS, ASA and center; §Adjusted for age, stage, PS, ASA, OCCI, CCI and center; ǁAdjusted for age, stage, PS, ASA, histology and center; ¶Un-adjusted; **Adjusted for age, stage, center, ASA and PS.